Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

Now Viewing

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Haumschild queries cost-effectiveness considerations around emerging dry eye disease (DED) therapies. Parekh states early DED identification and tailored treatment represents prevention, optimizing societal outcomes over following thousands of patients. Applying this population health approach can modify disease trajectory. Delaying intervention risks irreversible ocular surface damage and vision impairment despite eventual treatment. An upfront focus on appropriate therapy facilitates quality outcomes in a value-based model.

Kabiri discusses the responsibility for providers to address DED’s high prevalence with patient education and evidence-based recommendations, not just reacting to active complaints. Patients increasingly self-diagnose DED and expect specialist guidance on best practices. Effectively communicating around promising therapies enables access that impacts countless patients. Haumschild concurs this represents both an obligation and opportunity for optimal DED management benefiting all stakeholders.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.